scholarly article | Q13442814 |
P50 | author | Fabrizio Ensoli | Q55069671 |
Giovanni Paniccia | Q55302856 | ||
Stefania Bellino | Q55302859 | ||
Massimo Galli | Q56394582 | ||
Gioacchino Angarano | Q56424445 | ||
Adriano Lazzarin | Q56447702 | ||
Barbara Ensoli | Q21255143 | ||
Carlo Torti | Q30650659 | ||
Nicoletta Ladisa | Q30650673 | ||
Giampiero Carosi | Q30650713 | ||
Laura Sighinolfi | Q30650724 | ||
Alessandra Latini | Q51846044 | ||
Orietta Picconi | Q38546631 | ||
Stefano Rusconi | Q40213049 | ||
Giuseppe Tambussi | Q47158634 | ||
P2093 | author name string | Enrico Garaci | |
Aurelio Cafaro | |||
Vittorio Francavilla | |||
Angela Arancio | |||
Antonella Tripiciano | |||
Arianna Scoglio | |||
Cristina Ariola | |||
Cristina Iori | |||
Cristina Mussini | |||
Donato Scaramuzzi | |||
Fabrizio Soscia | |||
Florio Ghinelli | |||
Francesco Mazzotta | |||
Giovanni Di Perri | |||
Guido Palamara | |||
Maria J Ruiz Alvarez | |||
Massimo Campagna | |||
Massimo Di Pietro | |||
Olimpia Longo | |||
Raffaele Visintini | |||
Roberto Esposito | |||
Simone Marcotullio | |||
Stefano Bonora | |||
Vito S Mercurio | |||
P2860 | cites work | Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway | Q63351477 |
Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals | Q67982548 | ||
Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes | Q71396779 | ||
Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle | Q73263337 | ||
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy | Q73308229 | ||
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of | Q73848661 | ||
The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-infected typical progressors, but not in long-term non-progressors | Q82644038 | ||
A new subset of human naive CD8+ T cells defined by low expression of IL-7R alpha. | Q53545517 | ||
Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. | Q54057499 | ||
Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. | Q54734214 | ||
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia | Q57075698 | ||
Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy | Q57075703 | ||
The therapeutic phase I trial of the recombinant native HIV-1 Tat protein | Q57665211 | ||
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine | Q59511395 | ||
Candidate HIV-1 Tat vaccine development: from basic science to clinical trials | Q59647820 | ||
The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS | Q61641064 | ||
Immune activation and inflammation in HIV-1 infection: causes and consequences | Q22252860 | ||
The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein | Q24680024 | ||
Tat protein induces self-perpetuating permissivity for productive HIV-1 infection | Q24683211 | ||
Quantifying the uncertainty in forecasts of anthropogenic climate change | Q28141336 | ||
HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region | Q28252310 | ||
Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation | Q28280204 | ||
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology | Q28287124 | ||
Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction | Q28298254 | ||
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation | Q28361880 | ||
[21] Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction | Q29544077 | ||
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells | Q29616205 | ||
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy | Q30391183 | ||
Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells | Q33181641 | ||
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity | Q33220546 | ||
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells | Q33250088 | ||
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages | Q33255758 | ||
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome | Q33521702 | ||
Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains | Q33785321 | ||
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. | Q33941997 | ||
Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P | Q34055475 | ||
Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy | Q34068204 | ||
Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses | Q34105993 | ||
Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes | Q34297394 | ||
Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events | Q34344850 | ||
The survival benefits of AIDS treatment in the United States | Q34533291 | ||
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover | Q34692601 | ||
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment | Q34937231 | ||
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. | Q34985945 | ||
Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir | Q35155025 | ||
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype | Q35749755 | ||
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. | Q36379230 | ||
HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo | Q36384710 | ||
Human macrophages support persistent transcription from unintegrated HIV-1 DNA. | Q36511684 | ||
Early transcription from nonintegrated DNA in human immunodeficiency virus infection | Q36524970 | ||
The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. | Q36632734 | ||
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation | Q36639380 | ||
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines | Q36687077 | ||
Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. | Q36845770 | ||
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. | Q37178883 | ||
Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children | Q37194666 | ||
Cellular reservoirs of HIV-1 and their role in viral persistence | Q37196089 | ||
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy | Q37200979 | ||
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? | Q37220038 | ||
Evaluation of an automated instrument for viability and concentration measurements of cryopreserved hematopoietic cells. | Q50489286 | ||
The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children. | Q51047765 | ||
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. | Q51828622 | ||
Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. | Q51964201 | ||
Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. | Q51998598 | ||
Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. | Q52192468 | ||
Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo | Q37348552 | ||
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity | Q37378238 | ||
The challenge of finding a cure for HIV infection | Q37407598 | ||
Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? | Q37493607 | ||
Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate | Q37661107 | ||
Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection. | Q37768630 | ||
Antiretroviral therapy and management of HIV infection | Q37770721 | ||
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals | Q37771138 | ||
The preventive phase I trial with the HIV-1 Tat-based vaccine | Q38378021 | ||
Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. | Q39443021 | ||
Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy | Q39685944 | ||
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines | Q40419534 | ||
Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells | Q40508633 | ||
HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity | Q40517749 | ||
Regulation of HIV gene expression | Q41119975 | ||
Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma | Q41435232 | ||
Human immunodeficiency virus type 1 tat gene up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell line. | Q41615187 | ||
HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line | Q41714317 | ||
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients | Q41734588 | ||
Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. | Q41925734 | ||
The independent effect of drug resistance on T cell activation in HIV infection | Q42998780 | ||
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters | Q43671904 | ||
Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis | Q43872292 | ||
Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). | Q43967379 | ||
The trans-activator gene of the human T cell lymphotropic virus type III is required for replication | Q44579665 | ||
Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection | Q44674538 | ||
HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection | Q45341243 | ||
Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans | Q45710857 | ||
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection | Q45732713 | ||
HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy | Q45751207 | ||
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. | Q45761033 | ||
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. | Q45767659 | ||
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles | Q45887444 | ||
Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. | Q46077395 | ||
Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. | Q46200764 | ||
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy | Q47960975 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunization | Q1415366 |
P304 | page(s) | e13540 | |
P577 | publication date | 2010-11-11 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART | |
P478 | volume | 5 |
Q46698274 | "cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies". |
Q37054470 | A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice |
Q44280840 | A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. |
Q43973641 | A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies |
Q94587776 | A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy |
Q33916162 | An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge |
Q92906228 | Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease |
Q26764851 | Approaches to preventative and therapeutic HIV vaccines |
Q50066811 | Aptamers in HIV research diagnosis and therapy. |
Q36083803 | Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort |
Q27333734 | Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines |
Q89615834 | Cellular stress responses and dysfunctional Mitochondrial-cellular senescence, and therapeutics in chronic respiratory diseases |
Q34148683 | Challenges in HIV Vaccine Research for Treatment and Prevention |
Q42217775 | Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice. |
Q64259098 | Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study |
Q37967232 | Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV). |
Q44398270 | Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. |
Q38533881 | Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine |
Q30364312 | Developments in HIV-1 immunotherapy and therapeutic vaccination. |
Q42061242 | Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide |
Q35354848 | Expression of the IL-7 receptor alpha-chain is down regulated on the surface of CD4 T-cells by the HIV-1 Tat protein |
Q36242915 | HIV Infects Bronchial Epithelium and Suppresses Components of the Mucociliary Clearance Apparatus |
Q35867173 | HIV RNA suppression and immune restoration: can we do better? |
Q36864918 | HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent v |
Q35552889 | HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial |
Q36109585 | HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology |
Q34477471 | HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies |
Q36986644 | HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial |
Q35208314 | IL-7 receptor recovery on CD8 T-cells isolated from HIV+ patients is inhibited by the HIV Tat protein |
Q41468434 | Identification of a highly conserved surface on Tat variants |
Q37104090 | Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein |
Q33739129 | Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice |
Q34145979 | Interferon-alpha administration enhances CD8+ T cell activation in HIV infection |
Q37724091 | Lessons learned from HIV vaccine clinical efficacy trials |
Q58960764 | Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules |
Q37153763 | Molecular and Genetic Characterization of HIV-1 Tat Exon-1 Gene from Cameroon Shows Conserved Tat HLA-Binding Epitopes: Functional Implications |
Q26777222 | Mucociliary dysfunction in HIV and smoked substance abuse |
Q33603602 | Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication. |
Q57095865 | Natural SIV Infection |
Q38692205 | New challenges in therapeutic vaccines against HIV infection. |
Q38212101 | Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors |
Q36605014 | Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. |
Q92995413 | TGF-β1 increases viral burden and promotes HIV-1 latency in primary differentiated human bronchial epithelial cells |
Q35040673 | The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses |
Q37364423 | The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice |
Q34756847 | The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile |
Q42253045 | The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders. |
Q33864926 | The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study |
Q54217910 | The role of HIV Tat protein in HIV-related cardiovascular diseases. |
Q38013505 | Therapeutic vaccines against HIV infection |
Q83564526 | Transfer of the ability of HIV-1 Tat to raise an adjuvant-free humoral immune response to unrelated antigens |
Q36827396 | tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection. |
Search more.